{"id":"gabapentin-extended-release-tablets","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"5-10","effect":"Peripheral edema"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL940","moleculeType":"Small molecule","molecularWeight":"171.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gabapentin is an anticonvulsant and analgesic that works by modulating calcium influx through voltage-gated calcium channels, particularly those containing the alpha-2-delta-1 subunit. This reduces the release of glutamate, noradrenaline, and substance P, thereby decreasing neuronal excitability and pain signal transmission. The extended-release formulation provides sustained drug levels over 24 hours, improving convenience and potentially reducing dosing frequency compared to immediate-release formulations.","oneSentence":"Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:10.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postherpetic neuralgia"},{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Neuropathic pain conditions"}]},"trialDetails":[{"nctId":"NCT02633683","phase":"PHASE4","title":"An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS","status":"UNKNOWN","sponsor":"XenoPort, Inc.","startDate":"2016-01","conditions":"RLS","enrollment":144},{"nctId":"NCT02560766","phase":"PHASE4","title":"An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS","status":"UNKNOWN","sponsor":"XenoPort, Inc.","startDate":"2016-02","conditions":"RLS","enrollment":132},{"nctId":"NCT02633657","phase":"PHASE1","title":"A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS","status":"WITHDRAWN","sponsor":"XenoPort, Inc.","startDate":"2016-01","conditions":"RLS","enrollment":""},{"nctId":"NCT01080300","phase":"PHASE3","title":"Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women","status":"COMPLETED","sponsor":"Depomed","startDate":"2010-08","conditions":"Hot Flashes","enrollment":600},{"nctId":"NCT02987920","phase":"PHASE4","title":"Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-01","conditions":"Pain, Postoperative","enrollment":23},{"nctId":"NCT02252536","phase":"PHASE2","title":"HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2015-06","conditions":"Alcohol Use Disorder","enrollment":346},{"nctId":"NCT02424695","phase":"PHASE4","title":"Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome","status":"UNKNOWN","sponsor":"Cleveland Sleep Research Center","startDate":"2015-06","conditions":"Restless Legs Syndrome","enrollment":20},{"nctId":"NCT00748098","phase":"PHASE3","title":"Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-10","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":136},{"nctId":"NCT00755417","phase":"PHASE3","title":"Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women","status":"COMPLETED","sponsor":"Depomed","startDate":"2008-09","conditions":"Hot Flashes","enrollment":541},{"nctId":"NCT00777023","phase":"PHASE3","title":"Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.","status":"COMPLETED","sponsor":"Depomed","startDate":"2008-10","conditions":"Hot Flashes","enrollment":565},{"nctId":"NCT00636636","phase":"PHASE3","title":"Safety and Efficacy of Gabapentin in Postherpetic Neuralgia","status":"COMPLETED","sponsor":"Depomed","startDate":"2008-03","conditions":"Neuralgia,Postherpetic","enrollment":452},{"nctId":"NCT00511953","phase":"PHASE2","title":"Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women","status":"COMPLETED","sponsor":"Depomed","startDate":"2007-06","conditions":"Hot Flashes","enrollment":108},{"nctId":"NCT00712439","phase":"PHASE2","title":"Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Depomed","startDate":"2006-04","conditions":"Diabetic Peripheral Neuropathy","enrollment":147},{"nctId":"NCT00335933","phase":"PHASE3","title":"Safety and Efficacy of Gabapentin in Postherpetic Neuralgia","status":"COMPLETED","sponsor":"Depomed","startDate":"2006-05","conditions":"Neuralgia, Postherpetic","enrollment":378}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gabapentin Extended Release tablets","genericName":"Gabapentin Extended Release tablets","companyName":"Depomed","companyId":"depomed","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gabapentin Extended Release tablets are a small molecule medication used to treat various conditions, including pain, postoperative pain, hot flashes, restless leg syndrome, neuralgia, and postherpetic neuralgia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}